ARTICLE | Clinical News
FavId: Phase III started
September 27, 2004 7:00 AM UTC
Favrille began the double-blind, U.S. Phase III Favld-06 trial in 342 patients comparing placebo to FavId following treatment with Rituxan. The trial has an SPA. Rituxan rituximab is marketed for NHL...